ScreenerHero

NAMS NewAmsterdam Pharma Company N.V.

NAS · US · Healthcare · Biotechnology · newamsterdampharma.com
22.13USD-0.63%Mkt Cap: 2.65B $P/E: —

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.65B USD
Enterprise Value2.03B USD
Revenue (TTM)7.12M USD
Gross Profit7.12M USD
Net Income (TTM)-203.82M USD
Revenue/Share0.06 USD
Last Price22.13 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.56
PEG—
EV/EBITDA-8.31
EV/Revenue284.84
P/S373.84
P/B4.15
EPS (TTM)-2.11
EPS (Forward)-1.53
52W Range
21.025% of range42.21
52W High42.21 USD
52W Low21.02 USD
Profitability
Gross Margin100.00%
Oper. Margin-1752.61%
EBITDA Margin0.00%
Profit Margin-905.74%
ROE-29.82%
ROA-26.49%
Growth
Revenue Growth-80.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-147.78M USD
CapEx (TTM)246.00K USD
FCF Margin-636.97%
FCF Yield-1.71%
Net Debt-633.77M USD
Net Debt/EBITDA2.60
Balance Sheet
Debt/Equity0.00
Current Ratio9.03
Quick Ratio8.76
Book Value/Sh5.37 USD
Cash/Share5.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)49.85 USD
Upside (mean)+125.3%
Target Range37.04 USD – 59.59 USD
37.04+125.3% to mean59.59
# Analysts15
Ownership
Shares Out.119.54M
Float81.50M
Insiders0.90%
Institutions106.63%
Short Interest
Short Ratio12.0d
Short % Float15.33%
Short % Out.13.10%
Shares Short15.66M
Short (prev mo.)12.65M
Technical
SMA 5025.50 (-13.2%)
SMA 20031.10 (-28.8%)
Beta0.10
S&P 52W Chg15.78%
Avg Vol (30d)1.57M
Avg Vol (10d)1.79M
Technical Indicators
RSI (14)37.7
MACD-0.8844
MACD Signal-1.0153
MACD Hist.+0.1309
BB Upper24.93 USD
BB Middle22.96 USD
BB Lower20.99 USD
BB Width17.14%
ATR (14)1.336 USD
Vol Ratio (20d)0.72x